About

Prof. Dr. Berrin Pehlivan graduated from Hacettepe University Medical Faculty … With the motivation of cancer cases that Pehlivan encountered frequently in her family and surroundings, she turned onto Oncology and made observations in the Department of Radiation Oncology at Boston University where she spent her internship period. After completing her Radiation Oncology specialization training at Hacettepe University, she stayed abroad for a long time.

Improving herself constantly by researching global technologies in the cancer fight, Pehlivan took part in many scientific studies in France and Switzerland between 2004 and 2009. Continuing to her studies at the French European Cancerology Program, Lausanne University Radiation Oncology Department, Switzerland Villigen Paul Scherrer Institute Proton Therapy Center and France Orsay Proton Therapy Center, Pehlivan returned to Turkey to share her experiences with her own people at first hand.

After her studies at Başkent University and Akdeniz University Faculty of Medicine, she established Antalya Medstar Hospital Radiation Oncology Department under the Memorial Health Group.

Having put her signature under many national and international articles, scientific publications and projects, Pehlivan worked at Bahçelievler Medical Park Hospital, Göztepe Medical Park Hospital and Altınbaş University until the end of 2018. She also wrote a book called “Cancer in 50 Questions”. She continues to write articles for the Science Corner of “Cadde” Supplement of Milliyet Newspaper. Prof. Dr. Berrin Pehlivan currently trains the scientist of the future as a faculty member at Bahçeşehir University Radiation Oncology Department and continues to work in her own clinic.

Education

1993-2000Hacettepe University, Faculty of Medicine, Ankara/Turkey
1999Boston University Radiation Oncology Departement, Boston/USA
2001-2004Hacettepe University, Faculty of Medicine Radiation Oncology
Departement, Ankara/Turkey
2004-2005D.U.E.R.C.C. ‘Diplome Universitaire Europeen de Recherche Clinique en
Cancérologie’, Institut Gustave- Roussy, Paris/France
2005-2006‘Diploma Universitaire de Radiobiologie’, Institut Gustave-Roussy, Paris / France
2006-2007Fellowship, University Hospital of Lausanne, Radiation Oncology Departement, Lausanne/Switzerland
2007-2008‘Visiting Scientist’, Paul Scherrer Institute, Protontherapy Center, Villigen/Switzerland
2008-2009‘Visiting Scientist’ Orsay Protontherapy Center, Orsay/France
2009-2010Assistant. Prof., University of Baskent, Adana/Turkey
2010-2012Assistant. Prof., University of Akdeniz, Antalya/Turkey
2012-Associated Prof, Memorial Health Group, Medstar Antalya Hospital, Antalya/Turkey

Scientific Articles

  1. Yilmaz B, Somay E, Topkan E, Pehlivan B, Selek U. Pre-chemoradiotherapy low hemoglobin levels indicate increased osteoradionecrosis risk in locally advanced nasopharyngeal cancer patients. Eur Arch Otorhinolaryngol. 2023 Feb 7.
  2. Somay E, Yilmaz B, Topkan E, Kucuk A, Pehlivan B, Selek U. Initial neutrophil-to-lymphocyte ratio predicts radiation-induced trismus in parotid gland cancer. Oral Dis.2022 Nov 8.
  3. Somay E, Yilmaz B, Topkan E, Kucuk A, Haksoyler V, Pehlivan B, Selek U, Araz K. Hemoglobin-to-platelet ratio in predicting the incidence of trismus after concurrent chemoradiotherapy. Oral Dis 2022 Aug 29.
  4. Topkan E, Selek U, Kucuk A, Pehlivan Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas. J Inflamm Res. 2022 Sep 18;15:5413-5423.
  5. Topkan E, Selek U, Haksoyler V, Kucuk A, Durankus NK, Sezen D, Bolukbasi Y, Pehlivan B. Postchemoradiotherapy Neutrophil-to-Lymphocyte Ratio Predicts Distant Metastasis and Survival Results in Locally Advanced Pancreatic Cancers. Int J Clin Pract. 2022 Jan 31;2022:7473649.
  6. Yalcin K, Pehlivan B, Celen S, Bas EG, Kabakci C, Pashayev D, Daloglu H, Zhumatayev S, Uygun V, Karasu GT, Hazar V, Yesilipek A. Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL. J Pediatr Hematol Oncol2021 Mar 31.
  7. Kucuk A, Topkan E, Selek U, Haksoyler V, Mertsoylu H, Besen AA, Pehlivan B. High Measures of Pre-Chemoradiotherapy Platelet-to-Albumin Ratio Indicates Poor Prognosis in Locally Advanced Pancreatic Cancer Patients. Ther Clin Risk Manag. 2022 Apr 14;18:421-428.
  8. Topkan E, Selek U, Küçük A, Haksöyler V, Özdemir Y, Sezen D, Mertsoylu H, Besen AA, Bölükbaşı Y, Özyılkan O, Pehlivan B. Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis. J Oncol 2021 Jan 23;2021.
  9. Küçük A, Ozkan EE, Öztep SE, Mertsoyle H, Pehlivan B, Selek U, Topkan E. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. J Oncol 2020 Dec 16.
  10. Topkan E, Besen AA, Mertsoylu H, Kucuk A, Pehlivan B, Selek U. Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide. Int J Inflam. 2020 Jun 8;2020.
  11. Topkan E, Mertsoylu H, Kucuk A, Besen AA, Sezer A, Sezen D, Bolukbasi Y, Selek U, Pehlivan B. Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy. Gastroenterol Res Pract. 2020 Jul 30;2020.
  12. Topkan E, Ozdemir Y, Guler OC, Kucuk A, Besen AA, Mertsoylu H, Sezen D, Akdemir EY, Sezer A, Bolukbasi Y, Pehlivan B, Selek U.  Comparison of Involved Field Radiotherapy versus Elective Nodal Irradiation in Stage IIIB/C Non-Small-Cell Lung Carcinoma Patients Treated with Concurrent Chemoradiotherapy: A Propensity Score Matching Study. J Oncol. 2020 Sep 4;2020.
  13. Topkan E, Kucuk A, Ozdemir Y, Mertsoylu H, Besen AA, Sezen D, Bolukbasi Y, Pehlivan B, Selek U. Systemic Inflammation Response Index Predicts Survival Outcomes in Glioblastoma Multiforme Patients Treated with Standard Stupp Protocol. J Immunol Res. 2020 Nov 14;2020.
  14. Kucuk A, Ozkan EE, Eskici Oztep S, Mertsoylu H, Pehlivan B, Selek U, Topkan E. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. J Oncol2020 Dec 16;2020.
  15. Topkan E, Besen AA, Ozdemir Y, Kucuk A, Mertsoylu H, Pehlivan B and Selek U. Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Post-neurosurgical Radiotherapy plus Concurrent and Adjuvant Temozolomide. Mediators Inflamm. 2020 23;2020.
  16. Kucuk A, Topkan E, İkiz ED, Durankuş N, Senyurek S, Aydemir EY, Sezen D, Bolukbaşı Y, Selek U, Pehlivan B. Combination of stereotactic radiosurgery with immunotherapy: is it a new treatemnt option for brain metastases? Int Res J Oncol, 2020.
  17. Topkan E, Küçük A, Şenyürek S, Sezen D, Durankuş NK, Aydemir EY, İkiz ED, Bölükbaşı Y, Pehlivan B ve Selek U. Preoperative radiosurgery in management of brain metastases. J Cancer Tumor Int, 10(1):1-11, 2020.
  18. Topkan E, Küçük A, Sezen D, Senyürek S, Aydemir EY, Durankuş N, İkiz ED, Bolükbaşı Y, Pehlivan B ve Selek U. Common prognostic scoring system for patients presenting with brain metastases. Clin Oncol Res, 2020.
  19. Pehlivan B, Topkan E, Küçük A, Okumuş A, Sezen D, Bölükbaşı Y, Selek U. Stereotactic radiosurgery and targeted therapies for brain metastases from solid cancers. JAMMR,ISSN:2456-8899.
  20. Topkan E, Küçük A, Durankuş NK, Şenyürek Ş, Akdemir EY, Sezen D, İkiz ED, Bölükbaşı Y, Pehlivan B, Selek U. Radiosurgical management of brainstem metastasis. Int Res J Oncol, 2020 3(1):37-46.
  21. Sağlam Y, Bölükbaşı Y, Atasoy Aİ, Karaköse F, Alpan V, Selek U, Küçük A, Pehlivan B, Topkan E. Quality assurance in stereotactic radiosurgery and stereotactic body radiotherapy. Advances in Research 21 (7), 22-33.
  22. Topkan E, Küçük A, Şenyürek Ş, Sezen D, Durankuş NK, Akdemir EY, Sağlam Y, Bölükbaşı Y, Pehlivan B, Selek U. Radiosurgery techniques for brain metastases. JCTI 2020; 10, 1-14.
  23. Bölükbaşı Y, Selek U, Sezen D, Durankuş NK, Akdemir EY, Şenyürek Ş, Küçük A, Pehlivan B, Topkan E. Tumor cavity stereotactic radiosurgery for resected brain metastases. JCTI 2020, 10(2):15-30.
  24. Pehlivan B, Sengul K, Yesil A, Nalbant N, Ozturk O, Ozdemir Y, Topkan E. Dosimetric comparison of lung-sparing radiation therapy between volumetric arc therapy and helical tomotherapy for unresectable malignant pleural mesothelioma. BioMed Res Int, 2019.
  25. Pehlivan B, Kucuk A, Mertsoylu H, Topkan E. Current management of brainstem gliomas. Int. J.Adv. Res. 7(9), 2019.
  26. Topkan E, Pehlivan B. Radiation-induced abscopal effects on cardiovascular system. IndJMedResPharmSci, 6(9), 2019.
  27. Golusinski P, Di Maio P, Pehlivan B, Colley S, Nankivell P, Kong A, Hartley A, Mehanna H. Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck. Oral Oncol. 2019 Jan;88:145-152.
  28. Topkan E, Selek U, Ozdemir Y, Besen AA, Guler OC, Yildirim BA, Mertsoylu H, Findikcioğlu A, Ozyılkan O, Pehlivan B. Risk factors for .fatal pulmonary hemorrahage following concurrent chemoradiotherapy in stage 3B/C squamous-cell lung carcinoma patients. J Oncol 2018 Nov 1;2018.
  29. Topkan E, Yildirim BA, Guler OC, Parlak C, Pehlivan B, Selek U. Safety and palliative efficacy of single-dose-8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):774-80.
  30. Duman E, Cecen Y, Sındır B, Ozdemir B, Yıldırım M, Cecen S, Pehlivan B, Yavuz MN. Dosimetric evaluation of Adaptive Therapy in non-small lung cancer patients undergoing palliative thoracic Radiotherapy. Int J Hematol Oncol. 2015, 25:178-185.
  31. Mirimanoff RO, Ozsahin M, Thariat J, Ozyar E, Schick, Pehlivan B, Krengli M, Pellanda AF, Vess H. Cai L, Scandolaro L, Belacemi Y, Villa S, Igdem S, Lutsyk M, Miller RC. History of rare cancer network and past research. Rare Tumors. 2014 Aug 6;6(3):5462.
  32. Sarıca FB, Cekinmez M, Tufan K, Sen O, Onal HC, Mertsoylu H, Topkan E, Pehlivan B, Erdogan B, Altinors B. Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and efeectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma. Asian J Neurosurg. 2012 Oct;7(4):181-90.
  33. Topkan E. Parlak C, Topuk S, Pehlivan B. Influence on oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. BMC Cancer 2012 Oct 31;12:502.
  34. Pehlivan B, Ares C, Lomax T, Stadelmann O, Goitein G, Timmermann B, Schneider RA, Hug EB.: Temporal lobe toxicity analyasis after proton radiation therapy for skull base tumors. Int J Radiat Oncol Biol Phys 2012 Aug 1;83(5):1432-40.
  35. Topkan E, Parlak C, Kotek A, Yuksel O, Cengiz M, Ozsahin M, Pehlivan B. Impact of prophylactic cranial irradiation timing on brain relapse rates in patients with stage IIIB non-small-cell lung carcinoma treated with two different chemoradiotherapy regimens. Int J Radiat Oncol Biol Phys 2012 July 15;83(4):1264-71.
  36. Pehlivan B, Onal C, Yavuz M.: Retinoblastoma Tedavisinde Eksternal Radyoterapinin Rolü ve Radyoterapi Seçenekleri. Int J. Hematol Oncol. 2012, 22(2):1-9.
  37. Topkan E, Parlak C, Kotek A, Yapar AF, Pehlivan B. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol 2011 10,11:123.
  38. Topkan E, Topuk S, Oymak E, Parlak C, Pehlivan B. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. Am J Clin Oncol 2012; 35(3):284-9.
  39. Sarıca F, Tufan K, Çekinmez M, Şen O, Onal HC, Mertsoylu H, Pehlivan B, Erdoğan B, Altınors MN. Effectiveness of temozolomide treatment used at thesame time with radiotherapyand adjuvant temozolomid: concomitant therapy of glioblastoma multiforme:         multivariate analysis and other prognostic factors. J Neurosurg Sci. 2010; 54(1): 7-19.
  40. Ozsahin M, Gruber G, Olszyk O, Karakoyun-Celik O, Pehlivan B, Azria D, Roelandts M, Kaanders JH, Cengiz M, Krengli M, Matzinger O, Zouhair A.: Outcome and prognostıc factors ın olfactory neuroblastoma: a rare cancer network study. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):992-7.
  41. Yavuz MN, Topkan E, Yavuz AA, Aydin M, Onal C, Reyhan M, Kotek A, Pehlivan B, Yapar AF.: FDG-PET/CT Imaging-based taget volume delineation for preoperative conformal radiotherapy for rectal carcinoma. Int J Hematol Oncol 2010, 20(2):067-074.
  42. Pehlivan B, Topkan E, Onal C, Nursal GN, Yüksel O, Yavuz M, Yavuz A.: Comparison of CT and integrated PET-CT based radiation therapy planning in malign plevral mesothelioma patients. Radiat Oncol. 2009, 4:35.
  43. Pehlivan B, Luthi F, Matzinger O, Betz M, Dragusanu D, Bulling S, Bron L, Pasche P, Seelentag W, Mirimanoff RO, Zouhair A, Ozsahin M.: Feasibility and efficacity of accelerated weekly concomitant boost postopeartive radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer. Ann Surg Oncol. 2009, 16:1337-1343.
  44. Pehlivan B, Pichenot C, Casting M, Auperin A, Arriagada R, Bourhis J.: Interfractional set-up errors evaluation by daily electronic portal imaging of IMRT in head and neck cancer patients. Acta Oncol. 2009, 48(3):440-5.
  45. Pehlivan B, Zouhair A, Luthi F, Bron L, Pasche P, Dragusanu D, Azria D, Matzinger O, Mirimanoff RO, Ozsahin M.: Decrease in hemoglobin levels following surgery influences the outcome in head and neck cancer patients treated with accelerated postoperative radiotherapy. Ann Surg Oncol. 2009, 16:1331-1336.
  46. Onal C, Arslan G, Topkan E, Pehlivan B, Yavuz M, Oymak E, Yavuz A.: Comparison of conventional and CT-based planning for intracavitary brachytherapy for cervical cancer: target volume coverage and organs at risk doses. J Exp Clin Cancer Res. 2009 Jul 1;28:95.
  47. Onal C, Pehlivan B, Bal N, Topkan E, Kilinc F, Topuk S. : Sarcomatoid Carcinoma of the Urinary Bladder Treated with Adjuvant Radiotherapy: A Case Report. Clinical Medicine: Case Reports 2009:2 39-42.
  48. Onal C, Yuksel O, Topkan E, Pehlivan B. : Bilateral glomus tumor treated with PET-CT based conformal radiotherapy: case report. Cases Journal 2009, 2:8402.
  49. Atahan IL, Yıldız F, Ozyar E, Pehlivan B, Genç M, Köse M, Tulunay G, Ayhan A, Yuce K, Güler N, Kucukali T.: Radiotherapy in the adjuvant setting of cervical carcinoma: treatment, results, and prognostic factors. Int J Gynecol Cancer 2007, 17 (4): 813-820.
  50. Garcia R, Bourhis J, Pehlivan B, Pichenot C, Alfonsi M.: Intensity modulated radiotherapy for cancers of the upper aerodigestive tract. Cancer Radiother 2007, 11(6-7):353-7.
  51. Pehlivan B, Topkan E, Yavuz A.: Protonterapy in clinical use. Ege Tıp Dergisi, 50(1):1-6, 2011
Back to top button